Laddar...
Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models
MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...
Sparad:
| I publikationen: | Pharmaceuticals (Basel) |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
MDPI
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8308925/ https://ncbi.nlm.nih.gov/pubmed/34358080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14070654 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|